SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is being pulled into concerns over neocloud financing and possible industry consolidation after Elon Musk warned that many AI-compute providers could fail as debt access tightens. Traders debate whether NBIS is better positioned than weaker peers, citing its recent financing and customer contracts, while skeptics remain concerned about funding and buildout risks.

iShares Inc. - iShares MSCI Brazil ETF

iShares MSCI Brazil ETF

Lula da Silvas unexpected election victory over Flvio Bolsonaro is driving attention to EWZ, as traders react to concerns about Brazils political and economic outlook and the reversal of a rally tied to expectations of a Bolsonaro win. Reactions range from panic selling and bearish calls to buyers describing the selloff as an overreaction or buying opportunity; claims of election fraud remain speculation.

VXX tracks an index with exposure to futures contracts on the CBOE Volatility Index with average one-month maturity. Exposure resets daily.

Barclays Bank PLC - iPathÂ® Series B S&P 500Â® VIX Short-Term FuturesTM ETN

iPath S&P 500 VIX Short-Term Futures ETN

VXX is drawing attention after rebounding from a yearly low as traders watch for a pickup in market volatility and renewed demand for portfolio protection. Some see room for the volatility move to continue, while others view it as a short-lived pop and favor selling rallies given VXXs structural decay.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude climbs amid traders fears that renewed U.S.-Iran conflict and wider Middle East tensions could disrupt oil flows and infrastructure. Some traders expect the supply-risk premium to persist, while others argue the rally is overextended and could reverse if tensions ease or a deal emerges.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians quarterly results and forward guidance are the dominant focus, with traders weighing strong delivery growth and the R2 ramp against cash burn, margins, and execution concerns as the stock trades near recent lows. The autonomy-focused acquisition also draws interest, though views are split on whether it can meaningfully advance the business or adds expense.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPengs prolonged selloff toward its yearly lows has traders debating whether support can hold and whether the stock can rebound. Bullish discussion points to robotaxi trials and AI-chip technology, while concerns about weak Chinese EV demand, profitability and broader weakness in Chinese stocks remain prominent.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSM is drawing attention amid a steep selloff and uncertainty over Auvelitys launch for Alzheimers-related agitation, with investors focused on prescription growth and whether reported data capture demand through samples and long-term-care channels. Bulls expect the Q3 results to clarify the ramp and point to continued Auvelity growth; skeptics question adoption, high commercial spending, and the path to profitability, while managements silence has amplified concern.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensors decentralized-AI network and subnet growth are driving discussion, with traders debating whether commercial activity can translate into sustainable demand for TAO. Long-term believers are accumulating, while skeptics question the scale of adoption, revenue and token value capture.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

Elon Musks warning about failures and consolidation among neocloud providers has added to concerns over tight credit and debt-funded AI infrastructure expansion, weighing on IREN and peers. Traders are divided between fears of financing and execution risks and the view that IRENs customer contracts, power assets, and AI partnerships set it apart.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Elon Musks warning that neocloud providers could face failures and consolidation has intensified discussion of CoreWeaves debt-heavy AI infrastructure expansion and access to financing. Traders disagree over whether Musks comments are self-interested competitor rhetoric or confirmation of real credit and execution risks; bullish posts point to Nvidias backing and continued AI demand.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Spero Therapeutics Names Debra Jeske Zack As Chief Medical Officer

(RTTNews) - Spero Therapeutics, Inc. (SPRO), a clinical-stage biopharmaceutical company, on Monday said it has appointed Debra Jeske Zack as Chief Medical Officer...

Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody PR Newswire SAN...

Brains, AI Imaging, and Breakthrough Antibiotics Ignite Investor Buzz

The healthcare and biotechnology sector continues to generate a steady stream of meaningful catalysts as companies advance novel therapies, secure regulatory milestones, strengthen intellectual property portfolios, and expand commercialization efforts. Recent developments from CervoMed (NASDAQ:CRVO), Butterfly Network (NYSE:BFLY), NeOnc (NASDAQ:NTHI), Spero Therapeutics (NASDAQ:SPRO), GSK (NYSE:GSK), and IceCure Medical (NASDAQ:ICCM) highlight several emerging themes shaping the sector, including neurodegenerative disease treatment, AI-powered diagnostics, antimicrobial resistance, minimally invasive cancer care, and synthetic biology.

GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections

GSK wins FDA approval for Utebzi, the first oral carbapenem for complicated UTIs, further expanding its anti-infectives portfolio.

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii...

Compass Pathways Elects Kathleen Tregoning to Board of Directors

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of Directors at the annual general meeting of shareholders. Ms. Tregoning is expected...

Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Significant Growth in Short Interest

Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 737,720...

GSK Q1 Earnings Beat Estimates, Specialty Medicines Drive Sales Growth

GSK Q1 earnings and revenues beat estimates as Specialty Medicines lifted sales, with HIV, oncology and respiratory growth. The guidance for 2026 remains unchanged.

Spero Therapeutics (NASDAQ:SPRO) Share Price Passes Above 50 Day Moving Average   - What's Next?

Spero Therapeutics (NASDAQ:SPRO) Shares Pass Above 50-Day Moving Average - Here's What Happened...

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Spero Therapeutics Inc

GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled

Equity

Bearish Sentiment

British pharmaceutical company GSK PLC (GSK) and its Massachusetts-based partner Spero Therapeutics (SPRO) <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.gsk.com/en-gb/media/press-releases/pivot-po-phase-iii-study-for-tebipenem-hbr-stopped-early-for-efficacy-following-review-by-independent-data-monitoring-committee/">said</a> on Wednesday that they are stopping their late-stage trial evaluating the efficacy of its investigational oral treatment for complicated urinary tract infections (cUTI) earlier than expected following positive results.The treatment, called Tebipenem Pivoxil Hydrobromide (HBr), was developed by GSK and Spero. In September 2022, GSK entered into an exclusive license agreement with Spero Therapeutics for the development and commercialisation of Tebipenem HBr in all markets, except certain Asian territories.The early stop follows the trial meeting its primary goal of showing non-inferiority of Tebipenem HBr compared to an intravenous medicine in hospitalized adult patients with cUTI, including Pyelonephritis, where the infection spreads from the bladder to the kidneys.The decision follows a recommendation from an Independent Data Monitoring Committee (IDMC), based on an analysis of data from 1,690 patients enrolled in the study. The committee did not identify any new safety concerns beyond what has been reported in other studies with Tebipenem, the companies said.GSK said that it plans to work with U.S. regulatory authorities to include the data as part of a filing in the second half of the year.If approved, Tebipenem HBr would be the first oral carbapenem antibiotic for patients in the U.S. who suffer from cUTIs, GSK said. An estimated 2.9 million cases of cUTIs are treated annually in the U.S. alone, the company noted.The current standard of care for cUTIs includes carbapenem antibiotics, which are available for intravenous administration, requiring emergency department visits and hospitalization.SPRO stock rocketed 203% on Wednesday morning following the news, while NYSE-listed shares of GSK fell marginally.On Stocktwits, retail sentiment around SPRO jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘low’ to ‘extremely high’ levels. &nbsp;<figure class="image"><img style="aspect-ratio:623/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_28_at_9_09_53_AM_png_aff7b11b53.webp" alt="SPRO's Sentiment Meter and Message Volume as of 9:10 a.m. ET on May 28, 2025 | Source: Stocktwits " width="623" height="63"><figcaption>SPRO's Sentiment Meter and Message Volume as of 9:10 a.m. ET on May 28, 2025 | Source: Stocktwits&nbsp;</figcaption></figure>Meanwhile, retail sentiment around GSK rose from ‘neutral’ to ‘bullish’ territory, coupled with ‘low’ message volume.<figure class="image"><img style="aspect-ratio:626/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_28_at_9_11_15_AM_png_bcb11bf986.webp" alt="GSK's Sentiment Meter and Message Volume as of 9:10 a.m. ET on May 28, 2025 | Source: Stocktwits " width="626" height="66"><figcaption>GSK's Sentiment Meter and Message Volume as of 9:10 a.m. ET on May 28, 2025 | Source: Stocktwits&nbsp;</figcaption></figure><a href="https://stocktwits.com/symbol/SPRO">SPRO stock</a> is up by about 94% this year, while <a href="https://stocktwits.com/symbol/GSK">GSK shares</a> are up by about 16%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/abercrombie-and-fitch-post-strong-q1-2025-earnings/ch0oSjCRbsQ">Abercrombie &amp; Fitch Stock Soars After Upbeat Q1 Results: Retail Turns More Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

The early stop follows the trial meeting its primary endpoint of non-inferiority of Tebipenem HBr compared to an intravenous medicine in hospitalised adult patients with cUTI.

The early stop follows the trial meeting its primary endpoint of non-inferiority of Tebipenem HBr compared to an intravenous medicine in hospitalised adult patients with cUTI, including Pyelonephritis, where the infection spreads from the bladder to the kidneys. 


Glaxosmithkline plc - ADR

Vanguard Total Stock Market ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$1.11
Prev Close	$1.13
Open	$1.13
Dividend Yield	0.00%
50-Day Moving Average	$1.18
Beta	0.97
Avg. Volume	767,852.00
PE Ratio	10.16

52-Week High	$3.08
52-Week Low	$1.08
Market Capitalization	$64.64M
EPS (Annual)	$0.1452
Price to Book	1.46
Revenue Per Employee	$2.38M

Feed

News

Sentiment

Earnings

Fundamentals

Info

SPRO Fundamentals